



## A unique target against the key neurodegenerative mechanisms : toward disease modifying treatment

### **About us,**

ENCEFA is a biopharmaceutical company, incubated in the French Brain and Spinal cord Institute (ICM), located at the Pitié-Salpêtrière Hospital. It was founded in 2016.

Our monoclonal antibody, that modulates a novel target identified by ENCEFA, has demonstrated to act strongly on neuron's **autophagy, metabolism** and **inflammation**, that are three main components of **neurodegeneration**. Therefore, by its unprecedented mechanism of action and powerful effects, this antibody represents a promising advance in neurodegenerative pathologies and is expected to be effective on a large population of patients suffering from diseases without any treatment available.

So far, many advantages discovered :

- combined actions on different pathological component
- strong efficacy POC in vitro, ex vivo and in vivo
- preliminary safe results in vivo at high doses (few off-target effects).

Therefore, by its pleiotropic action, **ENCEFA's compound has the potential to become game-changing players in the area of neurodegenerative diseases : ALS, Multiple Sclerosis, Parkinson, Alzheimer...**



**LAURENCE BRESSAC**  
(CO-FOUNDER & CEO)



**DAMIEN TOULORGE**  
(CO-FOUNDER & CSO)



**SERGE GUERREIRO**  
(CO-FOUNDER & CSO)

### **What we have achieved...**



### **What we are planning for the futur...**



### **Contact us**

**Adress :** iPEPS - ICM Institut du Cerveau et de la Moelle épinière - Hôpital de la Pitié Salpêtrière  
47-83 Boulevard de l'Hôpital - 75013 PARIS - France EU

**Email :** [contact@encefa.com](mailto:contact@encefa.com)